Tonix Pharmaceuticals Holding Corp. (TNXP) is a publicly traded Healthcare sector company. As of May 21, 2026, TNXP trades at $14.21 with a market cap of $227.32M and a P/E ratio of -0.99. TNXP moved +5.47% today. Year to date, TNXP is -4.73%; over the trailing twelve months it is -51.51%. Its 52-week range spans $6.76 to $130.00. Analyst consensus is strong buy with an average price target of $41.33. Rallies surfaces TNXP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in TNXP news today?
Tonix to Unveil April 2021–2024 Fibromyalgia Claims Data at ISPOR 2026: Tonix Pharmaceuticals will present a retrospective analysis of U.S. fibromyalgia patients using April 2021–April 2024 claims data at ISPOR 2026, highlighting real-world insights on TONMYA. TONMYA, approved August 15, 2025 and launched November 17, 2025, is the first new fibromyalgia treatment in over 15 years.
Tonix to Unveil April 2021–2024 Fibromyalgia Claims Data at ISPOR 2026: Tonix Pharmaceuticals will present a retrospective analysis of U.S. fibromyalgia patients using April 2021–April 2024 claims data at ISPOR 2026, highlighting real-world insights on TONMYA. TONMYA, approved August 15, 2025 and launched November 17, 2025, is the first new fibromyalgia treatment in over 15 years.
Does Rallies summarize TNXP news?
Yes. Rallies summarizes TNXP news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is TNXP research on Rallies investment advice?
No. Rallies provides research, data, and educational context for TNXP. It does not provide personalized investment advice.
